CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL

December 03, 2016

SEATTLE - In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center.

Fred Hutch researchers will present their findings in an oral presentation at 7:45 a.m. Dec. 3 at the American Society of Hematology Annual Meeting and Exposition in San Diego.

Almost all of the 24 patients in the study had cancer that had advanced despite treatment with a newly approved drug called ibrutinib - an ominous indicator for patient survival. Most patients also had chromosomal markers in their leukemia cells that put them at high risk - "predictors of a bad response to most standard therapies," said Dr. Cameron Turtle, a hematologist/oncologist in the Clinical Research Division at Fred Hutch who co-leads the trial with colleagues Drs. David Maloney and Stanley Riddell.

Turtle's presentation will focus on the results in a subgroup of patients who received the CAR T-cell infusion using preferred chemotherapy and CAR T-cell doses that evolved from recent trial data. Fourteen of the 19 restaged patients experienced a partial or complete regression of the disease in their lymph nodes. Of the 17 who had leukemia in their marrow when they enrolled in the trial, 15 saw the marrow become cancer-free after receiving CAR T-cells.

"These are all heavily pretreated patients who've gone through many previous therapies," Turtle said. "It's very pleasing to see patients with refractory disease respond like this."

Participants with the highest number of CAR T-cells in their blood after infusion were the most likely to have their disease disappear from bone marrow after CAR T-cell infusion. Side effects included high fevers, due to activation of CAR T-cells, and neurologic symptoms. Although one patient died from severe toxicity, the side effects experienced by other patients in the study were temporary.

In a separate poster presentation from 5:30 to 7:30 p.m. on Dec. 3, the researchers will share their findings in a detailed characterization of the side effects of CD19 CAR T-cells. The poster session presentation is embargoed until 9 a.m. Dec. 3 - just over an hour after the embargo lifts for the CLL study results. Turtle and his colleagues identified certain biomarkers in patients' blood the day after infusion that were associated with the later development of the most severe toxicities. The researchers hope these biomarkers could eventually lead to tests to predict and mitigate the most serious side effects.

CAR T-cell therapy is accomplished by engineering T cells extracted from each patient's blood. A modified virus delivers genetic instructions into the cells for making a CAR, or chimeric antigen receptor, a synthetic molecule that allows T cells to recognize and kill cells bearing a particular target. In this case, the target is CD19, a molecule found on the surface of certain blood cells, including CLL cells, and the T cells are a carefully selected, one-to-one combination of two functionally different subsets if T cells. After the CAR T-cells are grown in the lab and the patient has received chemotherapy, the new CAR T-cells are infused back into the patient.

CD19 CAR T-cell studies at Fred Hutch are unique because the researchers engineer specific subsets of cells from the patient and formulate the cell product to be uniform. By creating CAR T-cells with a defined composition of T cell subsets, the researchers can improve the link between the dose of cells a patient receives and what they experience afterward - not just benefits, but also potential side effects.

Patients in the trial are seen at Seattle Cancer Care Alliance, Fred Hutch's clinical care partner.
-end-
Funding for this study was provided by NCI (National Cancer Institute) R01 CA136551; NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) P30 DK56465; NCI P30 CA15704; Life Science Discovery Fund; Juno Therapeutics and philanthropists.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.



Contact:


Sandy Van
Svan2@fredhutch.org
media@fredhutch.org
Tel. 808-526-1708 (o)
Tel. 808-206-4576 (m)

Fred Hutchinson Cancer Research Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.